Willingness to get vaccinated against Covid-19 and attitudes toward vaccination in general.
Willingness to get vaccinated against Covid-19 and attitudes toward vaccination in general.
复制标题
愿意接受COVID-19的疫苗接种和一般疫苗接种的态度。
DOI：
10.1016/j.vaccine.2021.05.069
复制
发表时间：
2021-07-30
期刊：
影响因子：
5.5
通讯作者：
Tubeuf S
中科院分区：
文献类型：
--
作者：
Kessels R;Luyten J;Tubeuf S
要达到群体免疫，需要大量接种Covid-19疫苗。2020年10月，对2060名比利时人的代表性样本进行了调查。回归分析确定了与接种Covid-19疫苗的意愿以及对疫苗接种的总体态度相关的预测因素。34%的参与者报告说他们肯定会接种Covid-19疫苗，39%的人表示他们“可能”会接种疫苗。预期摄入与年龄、对政府应对Covid-19大流行的看法、医疗风险、口语、性别密切相关，在较小程度上与是否认识因Covid-19住院的人有关。对疫苗接种的态度也确定了类似的预测因子。在54岁以下年龄组中，Covid-19疫苗犹豫更为明显。我们进一步分析了17% （N = 349）的样本，发现他们一般赞成接种疫苗，但不愿意接种Covid-19疫苗。他们主要是女性，年轻，讲法语，受教育程度略低，有工作，不属于Covid-19风险群体。他们对政府应对疫情的方式非常不满，也不知道有人因新冠肺炎住院。Covid-19疫苗的疫苗犹豫率高于其他疫苗。一般来说，一部分人相信疫苗接种的效用，但对Covid-19疫苗犹豫不决，这部分人是开展量身定制的宣传活动的主要利益群体，以达到群体免疫所需的疫苗覆盖率。
High uptake of Covid-19 vaccination is required to reach herd immunity. A representative sample of 2,060 Belgians were surveyed in October 2020. Regression analyses identified the predictors associated with willingness to get vaccinated against Covid-19, and attitudes toward vaccination in general. 34% of the participants reported that they will definitely get vaccinated against Covid-19 and 39% that they would “probably”. Intended uptake was strongly associated with age, opinion on the government’s dealing with the Covid-19 pandemic, medical risk, spoken language, gender, and to a lesser extent with having known someone who was hospitalised because of Covid-19. Similar predictors were identified for attitudes to vaccination in general. Covid-19 vaccine hesitancy was more marked in age groups below 54 years old. We further analysed a sample of 17% (N = 349) found favourable to vaccination in general but not willing to be vaccinated against Covid-19. They were mainly female, young, French speaking, slightly less educated, working, and did not belong to a Covid-19 risk group. They were very dissatisfied with the government’s dealing with the pandemic, and did not know someone who was hospitalised because of Covid-19. Vaccine hesitancy was higher for Covid-19 vaccines than for other vaccines. The part of the population being convinced of the utility of vaccination in general but hesitant about the Covid-19 vaccine is a primary interest group for tailored communication campaigns in order to reach the vaccine coverage needed for herd immunity.
登录
查看更多内容
影响因子：
5.9
作者：
Khubchandani J;Sharma S;Price JH;Wiblishauser MJ;Sharma M;Webb FJ
通讯作者：
Webb FJ
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1016/s2468-2667(21)00012-8
发表时间：
2021-04
期刊：
The Lancet. Public health
影响因子：
--
作者：
Schwarzinger M;Watson V;Arwidson P;Alla F;Luchini S
通讯作者：
Luchini S
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
3.2
作者：
Marshall, Gary S.
通讯作者：
Marshall, Gary S.